/l, Hb 9.5 g per 100 ml and platelet count 61 Â 10 9 /l. A BM biopsy showed infiltration by blastic cells CD19 þ , CD10 þ , CD34 þ and TdT þ , consistent with B-cell precursor ALL. Cytogenetic studies revealed 100% Ph þ metaphases. The presence of an e1a2 transcript (p190 BCRÀABL1 protein) was shown by reverse transcriptase-PCR. Both his mediastinum and cerebrospinal fluid were free of disease. Induction therapy with the DFCI-ALL Consortium Protocol 01-91 scheme (doxorubicin, VCR, high-dose MTX, L-asparaginase and prednisone) 3 for high-risk ALL was started along with CNS prophylaxis. A day 28 BM aspirate showed 20% blasts. He was deemed to be primary resistant and intensification therapy was started as per the DFCI scheme (doxorubicin, VCR, L-asparaginase, 6-MP and prednisone) with the addition of imatinib mesylate 600 mg daily. Intrathecal therapy was administered twice weekly. Four weeks after intensification was started, the patient achieved a complete cytogenetic response (CCyR). A decision was made to proceed immediately with allo-SCT from his HLA-identical brother. In July 2003, he received a conditioning regimen that involved TBI (2400 cGy) and CY. He engrafted on day 11 and his post transplant course was complicated by increased liver function tests without evidence of GVHD. A short course of MTX and CYA until day 100 post transplant was given as GVHD prophylaxis. In March 2004, the patient presented with fever, WBC 69 Â 10 9 /l, Hb 15.7 g per 100 ml and platelet count 204 Â 10 9 /l. The cerebrospinal fluid was infiltrated with leukemic cells and the Ph was detected again in the BM, along with loss of chromosome Y. Therapy with hyperCVAD and imatinib 800 mg daily was commenced. At day 14 of therapy, 5 Â 10 7 CD3 þ T cells from his HLA-identical brother were infused. A cerebrospinal fluid analysis was unremarkable and a BM biopsy showed a diploid karyotype without evidence of Ph chromosome. Microsatellite polymorphism analysis revealed the presence of 100% donor cells. The second cycle of hyperCVAD was complicated by seizures and a subdural hematoma that required drainage. Intrathecal therapy was withheld during this cycle. CCyR was confirmed in BM and he continued chemotherapy. In July 2004, the patient received his fourth hyperCVAD cycle, after which he developed respiratory insufficiency and leukoencephalopathy with recurrent seizures that kept him hospitalized for 6 weeks. A decision was made to withhold further chemotherapy. He remained in CCyR and the imatinib dose was reduced to 400 mg daily because of elevated liver function tests.
In March 2005, a second relapse was documented and he was referred to the MD Anderson Cancer Center. He had 59% CD10 þ , TdT þ lymphoblasts in the BM and 85% of the interphase cells were Ph þ by FISH. The F317L mutation in BCR-ABL1 was detected. The BCR-ABL1/ABL1 ratio was 100%. Cytogenetic studies revealed the presence of t(9;22)(q34;q11.2) along with -2, del(7)(p13p21), del(12)(p11.2) in 80% of metaphases, indicating clonal evolution. Dasatinib 70 mg twice daily was started ( Figure 1 ). Three weeks later, the patient achieved a CCyR and the BCR-ABL1/ABL1 ratio was 10.01%. BCR-ABL1 transcript levels became undetectable 22 weeks into dasatinib therapy in both peripheral blood and BM, and PCR-based microsatellite polymorphism analysis of the peripheral blood revealed a pattern identical to that of the donor in 100% of myeloid and T cells. The patient remained in CCyR on dasatinib for 16 months, after which he developed CNS relapse. The F317L mutation was again detected. He received another cycle of hyperCVAD in combination with dasatinib at 40 mg daily and intrathecal ara-C and MTX. The patient attained a new CCyR, as evidenced in a BM aspirate and biopsy, but given his poor performance status, no further chemotherapy was given. Nonetheless, single-agent dasatinib therapy was continued. Six months later, a new CNS relapse was documented. Dasatinib therapy was stopped and imatinib therapy 400 mg daily was started along with intrathecal ara-C. In spite of the lack of clinical data and the potential pharmacological interactions, therapy with nilotinib 400 mg twice daily and dasatinib was subsequently instituted in addition to imatinib and dexamethasone, but it failed to control the disease. Over the ensuing months, the patient's clinical course was punctuated by spastic paraparesis and multiple episodes of pneumonia, neutropenic fever and bilateral pleural effusion. The patient died of refractory Ph þ ALL and sepsis.
Therapy for Ph þ ALL is associated with CR rates of 80-90%, but most patients relapse quickly and succumb to the disease. The Ph represents the single worst prognostic factor in Ph þ ALL, occurring in approximately 3-4% of patients between 10 and 19 years of age. 4 Currently, allo-SCT is considered standard therapy in Ph þ ALL in first CR. 5 However, the combination of cytotoxic chemotherapy with imatinib results in eradication of BCR-ABL1 transcripts and durable remissions without allo-SCT in a subset of patients. Given the enhanced activity of dasatinib against BCR-ABL1 kinase, and its high potency against SRC kinases, which have been shown to be crucial for induction of Ph þ ALL, 6 this tyrosine kinase inhibitor has emerged as an attractive therapeutic strategy for Ph þ ALL, particularly in combination with active chemotherapy regimens for ALL. 7 This case not only exemplifies the activity of dasatinib in combination with hyperCVAD in this setting, but also underscores two important aspects of dasatinib therapy in patients with Ph þ leukemia. First, although dasatinib has been shown to overcome the resistance posed by a wide spectrum of BCR-ABL1 mutations, with the exception of T315I, some mutations conferring intermediate resistance to this agent may be problematic in clinical practice. Several amino-acid substitutions affecting residue 317 have been described in patients with Ph þ leukemia resistant to dasatinib. The most frequent of them, F317L, has been shown to induce a 9-to 13.5-fold increase of dasatinib IC 50 with respect to unmutated BCR-ABL1 in cellular assays. 8 Structural studies have shown that the aromatic ring in the side chain of phenilalanine 317 interacts directly with the pyrimidine and thiazole rings of dasatinib. 9 In some instances, the presence or the emergence of BCR-ABL1 F317L has been associated with clinical resistance and poor outcomes to dasatinib therapy despite initial response. 10 Second, therapy with highly active targeted agents in the post-allo-SCT setting may reverse the malignant hematopoietic phenotype to a benign donor-derived phenotype. In the present case, dasatinib therapy induced a molecular response and restored a pattern of hematopoiesis of donor origin only a few weeks after the start of this tyrosine kinase inhibitor. This occurrence is in all likelihood a direct consequence of the depletion of the malignant Ph þ clone induced by dasatinib, which allows small populations of cells of donor origin to repopulate the patient's hematopoiesis with Ph-negative progenitors, as evidenced by PCR-based microsatellite polymorphism analysis. To the best of our knowledge, this phenomenon has never been reported after dasatinib therapy or any other chemotherapy employed for the treatment of Ph þ ALL. This type of response, although likely to be transient, may provide a window of opportunity for the institution of more definitive therapy (that is, a second allo-SCT from a different donor) in this high-risk subset of patients. % BCR-ABL1/ABL1 ratio Dasatinib Figure 1 Response to dasatinib therapy after failure of imatinib and allo-SCT. After 22 weeks on dasatinib therapy, the patient achieved a complete molecular response and exhibited complete donor chimerism.
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